Alikhanov's industry report Biotech and medicine plans

Oct 5

Alikhanov describes a Kurchatov bioeconomy research centre, an interagency skills centre being formed and mapping completed for 28 of 36 priority chains. He cites Organic Acids/Citron citric-acid production with a planned 2028 second phase, a 90-tonne collagen facility and Norkem/Bioamid biocatalysis developed with Kurchatov, claiming technology sales even to countries he calls unfriendly. He emphasizes university engineering centres. In the complete pharmaceutical follow-up he gives localization goals of 90% of essential medicines and over 40% domestic medical devices, proposed support for 112 projects with 115 billion rubles by 2030 and 200 drug INNs, and industry investment of about 115 billion over a year and a half. He reports agreement at that morning's breakfast to try to adopt Phase III trial reimbursement by year-end and develop Phase I/II reimbursement with Innopraktika. These mechanisms remain planned. He also praises FMBA-linked sensory-feedback prostheses, saying more than a dozen people are walking in clinical trials, and describes other rehabilitation developments.

In his BIOPROM pharmaceutical answer, Alikhanov gives domestic-medicine and medical-device localization targets, intended support for 112 projects and 200 drug INNs, and reports industry investment. He says that morning's breakfast agreed to try to adopt Phase III trial reimbursement by year-end and introduce Phase I/II support with Innopraktika. The reimbursement mechanisms are proposed and under development; no adopted resolution or paid reimbursement is established.